Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN). Activation of TLR8 enhances natural killer cell activation, increases...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietsch, Gregory N., Lu, Hailing, Yang, Yi, Morishima, Chihiro, Chow, Laura Q., Disis, Mary L., Hershberg, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771163/
https://www.ncbi.nlm.nih.gov/pubmed/26928328
http://dx.doi.org/10.1371/journal.pone.0148764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771163/
https://www.ncbi.nlm.nih.gov/pubmed/26928328
http://dx.doi.org/10.1371/journal.pone.0148764

Ejemplares similares